Immunotherapy and Immune Responses

This paper develops a modular saponin-based nanoparticle adjuvant platform incorporating TLR agonists, showing improved vaccine potency and breadth against COVID-19 and HIV in mice.

This study develops CD45-targeted immunocytokines that localize to immune cells in tumors and lymph nodes, eradicating both treated and distant tumors in mouse models.

This study reprograms tumor cells in vivo to function as dendritic cells, leading to tumor regression and long-term immunity in mouse models.

This study shows KDM5C regulates dendritic cell (DC) heterogeneity and function by modulating epigenetic programming and subset balance, affecting immune responses to infection.

This study examines how protein conformational stability affects immunogenicity in mice when antigens are administered with adjuvants, focusing on the CH2 domain.

The paper identifies a TCR specific to KRAS-G12V neoantigen and characterizes its structural interaction with HLA-A3, revealing challenges in targeting this mutation.

This paper describes a novel vaccination platform using crosslinking polymers to enhance humoral immunity and dendritic cell activation in lymph nodes without adjuvants.

This study shows that AMPK activation makes human dendritic cells more tolerogenic by altering their metabolism, specifically increasing RALDH activity and changing lipid and glucose metabolism.

This study shows that PIKfyve inhibition enhances dendritic cell function and improves immunotherapy efficacy in tumor models.

This paper develops ePAC, a cancer vaccine using PEG10-based virus-like particles to deliver neoantigens and adjuvants, showing efficacy in preclinical models.

The paper shows that ALCAM-mediated synapses between DC1 and CD8 T cells decrease in advanced lung tumors, impairing immune responses.

This study compares the effects of two host preconditioning methods on the antitumor activity of adoptively transferred Th17 cells, finding that total body irradiation enhances their efficacy more than chemotherapy.

This study investigates how a synthetic immune niche modulates T-cell proliferation and cytotoxicity, finding that these properties are negatively correlated and differentially regulated by activation mode.

This study engineers migrasome-like vesicles (eMigrasomes) using hypotonic shock to create a stable, thermally robust vaccine platform that elicits strong immune responses.

The paper identifies a novel plasmacytoid dendritic cell lineage in mice and humans derived from common lymphoid progenitors, characterized by unique gene expression and functional properties.

This paper develops a novel microporous biomaterial vaccine platform, VaxMAP, which enhances antibody-mediated immunity against viral infections compared to traditional vaccines.

The paper identifies SREBF2 as a regulator of mregDC development and function in the tumor microenvironment, highlighting it as a therapeutic target for immune tolerance.

This study identifies high-quality neoantigens in follicular lymphoma patients using WES and RNA-Seq, and initiates a clinical trial of personalized neoantigen vaccines combined with PD-1 blockade.

This study evaluates the immunogenicity of different liposome-based adjuvants and injection sites in pigs, finding that adjuvants boost IgA and IgG but show limited differences in cell-mediated immunity.

This study uses pH-sensitive peptides to deliver MHC-binding antigens to cancer cells, enhancing T cell activation for immunotherapy.

The paper uses a patient-derived explant model to show metformin enhances dendritic cell maturation by inhibiting complex I, improving anti-tumor immunity when combined with venetoclax.

This study shows that bladder BCG immunotherapy reprograms hematopoietic stem cells to enhance anti-tumor immunity in mice and humans.

The paper shows that DC-based therapy enhances CD8 T cell responses to neoantigens in lung tumors, particularly in high TMB tumors.

This paper develops a mathematical model to optimize vaccine doses for personalized neoantigen melanoma vaccines and validates it through in silico experiments on six patients.

This study demonstrates that self-assembled protein vesicles can deliver full-size antigens to induce strong immune responses in mice.

This paper introduces a centrifugation-based method for isolating murine bone marrow to differentiate dendritic cells, which increases cell numbers and yields more type 1 conventional dendritic cells.

This study shows IL-15 treatment enhances the anti-tumor efficacy of sipuleucel-T by increasing CD8+ T-cell and CD56+ NKT subset activity in prostate cancer.

A 'shock-and-lock' nanoparticle agonist activates STING in type 1 conventional dendritic cells to enhance antitumor immunity with associated biomarkers.

Dendritic cells maintain RNA and protein levels for conditionally deleted genes by siphoning material from neighboring cells using a novel mechanism.

This study describes a patient with diffuse midline glioma who achieved remission after vaccination with an H3K27M peptide vaccine, showing robust T and B cell responses across diverse HLA alleles.